Clinical Trial Update: Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing ABL001 (asciminib) to bosutinib in chronic myeloid leukemia in chronic phase patients previously treated with ≥2 TKIs, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• ABL001 (asciminib)
• Bosutinib (bosutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2022-02-15